drugset
drugset / Trial / NCT05431634

Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy Participants

NCT05431634 ↗

Phase 1 Completed 49 enrolled Alumis Inc
RandomizedSequentialDouble-blindTreatment

Summary

Multiple Dose Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ESK-001 in Healthy Participants

Timeline

Start
2022-05-12
Primary completion
2022-12-01
Completion
2022-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject ENVUCITINIB Small molecule — —

Indications

No indication recorded.